
Isomorphic Labs, the AI drug-design company spun out of Google DeepMind in 2021, has raised $5 billion in Series C funding. The round was co-led by Greenoaks and Sequoia Capital, alongside new investor Andreessen Horowitz and several other new backers, with continued significant investment from Alphabet. All existing investors also participated, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund, the company said on November 17.
The raise comes roughly six months after a $2.1 billion Series B in May. Isomorphic did not disclose its valuation; Bloomberg had reported earlier this month that the company was seeking to raise at about $50 billion.
The company said the capital will scale its proprietary drug design engine, IsoDDE, which combines AI simulation models across therapeutic areas and drug modalities, and fund translational and clinical development infrastructure. Isomorphic cited positive preclinical results in internal oncology and immunology programs and in partnered work; it has struck deals with Eli Lilly, Novartis and Johnson & Johnson. Founder and CEO Demis Hassabis has said the goal is a platform capable of producing hundreds of drugs a year, and Bloomberg reported more than 20 programs under way.
The financing extends a record year for drug-discovery startups, which have raised $23.2 billion in 2026, according to figures cited by Quartz. It also shows how crossover and growth investors are underwriting AI platforms that remain pre-clinical, betting that computational design can compress the time and cost of bringing a molecule to trial.
For venture and growth allocators, the round is a reminder that mega-rounds are increasingly concentrated in a small set of AI-native companies with strategic backers and deep balance sheets behind them. The key milestone now is clinical: Isomorphic has said regulatory filings for its first oncology program are progressing and that it expects further news in 2027, and the valuation investors have paid will ultimately be judged on human data.